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Background
Natriuretic peptides have potent natriuretic and vasodi-
lator properties, reduce sympathetic drive, inhibit aldos-
terone secretion and have antiproliferative and
antihypertrophic properties [1]. Increasing the concen-
tration of natriuretic peptides through neprilysin (NEP)
inhibition thus represents a therapeutic approach with
the potential to confer cardiac, vascular and renal pro-
tection. Prior research, however, has suggested that the
clinical benefits from NEP inhibition can be best lever-
aged if the renin-angiotensin-aldosterone system
(RAAS) is simultaneously inhibited.
Results
LCZ696 is a first-in-class angiotensin receptor neprilysin
inhibitor (ARNI) which provides concomitant inhibition
of NEP and the angiotensin receptor. Ingestion of
LCZ696 delivers systemic exposure to AHU377 (which
is then rapidly metabolized to LBQ657, a specific NEP
inhibitor) and to valsartan (an angiotensin II receptor
blocker). LCZ696 treatment is associated with dose-
dependent increases in plasma cGMP, renin activity and
angiotensin II, consistent with the drug’s dual mechan-
ism of action; a dose of 200-400 mg LCZ696 achieves
approximately 90% of its maximal NEP inhibition [2].
In a large Phase 2 study in hypertensive patients
(n=1328), LCZ696 400mg and 200mg once daily
reduced mean office systolic and diastolic blood pres-
sure (BP) by an additional 6/3 and 5/3 mmHg compared
with valsartan 320 and 160 mg, respectively (both
P<0.05); 24-hour ambulatory BP monitoring results were
consistent with office BPs. Pulse pressure was also low-
ered to a greater extent with LCZ696 than the respec-
tive valsartan groups (both P<0.05) [3]. In chronic heart
failure patients (n=27), after 3 weeks treatment, LCZ696
200 mg bid increased plasma cGMP levels while
decreasing plasma NT-proBNP and plasma aldosterone
levels (all P<0.01) as compared to baseline values (4).
The Phase III PARADIGM-HF study is evaluating
whether LCZ696 is superior to enalapril in delaying the
time to cardiovascular mortality or first occurrence of
heart failure (HF) hospitalization in patients with HF
and reduced ejection fraction [4]. The Phase II PARA-
MOUNT study is evaluating LCZ696 for HF patients
with preserved ejection fraction [5]. Both studies are
ongoing.
Conclusion
Dual inhibition of neprilysin and the angiotensin recep-
tor with LCZ696 may represent an attractive therapeutic
approach for a range of cardiovascular diseases, includ-
ing hypertension and heart failure, in which vasocon-
striction, volume overload and neurohormonal
activation play a part in pathophysiology.
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